Marquette communication professor receives National Communication Association award
Dr. Lynn Turner will be honored with the National Communication Association’s Bernard J. Brommel Award for Outstanding Scholarship or Distinguished Service in Family Communication.
MILWAUKEE – Dr. Lynn Turner, professor of communication studies at Marquette University, will be honored with the National Communication Association’s Bernard J. Brommel Award for Outstanding Scholarship or Distinguished Service in Family Communication. Turner and her co-author Richard West will be honored at the NCA 100th Annual Convention in Chicago on Saturday, Nov. 22.
Turner, who has been at Marquette since 1985, directs the family studies minor in the Diederich College of Communication. Her research focuses on family communication, gender and communication, and work/family intersections. She has served as past president of the National Communication Association, the Central States Communication Association, and the Organization for the Study of Communication, Language, and Gender. In 2012, Turner was inducted into the Central States Communication Association’s Hall of Fame and received the Diederich College of Communication’s research award.
“This is a great and well-deserved honor,” said Dr. Lori Bergen, dean of the Diederich College of Communication. “Lynn is nationally recognized for her excellence as a scholar and leader in the field, and we’re fortunate to have her as a colleague and to have our students benefit from her informed teaching.”
The NCA advances communication as the discipline that studies all forms, modes, media and consequences of communication through humanistic, social scientific and aesthetic inquiry. As an NCA award recipient, Turner joins a venerable group of scholars and educators who have been honored for achieving excellence in research, teaching and service.
Recent Press Releases by Marquette University
Troy leads a billion-dollar health system that is dedicated to children and employs nearly 5,000 people throughout the state.
Pudner has managed political campaigns for almost three decades.
The investment will finance key clinical trials of the company’s most promising compound targeting neuropsychiatric disorders.